Medical/Pharmaceuticals

Shilpa Medicare Secures SEC-CDSCO Nod for Nor-Ursodeoxycholic Acid Tablets, Eyes Market Launch for NASH

RAICHUR, India , March 12, 2025 /PRNewswire/ -- Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the Subject Expert Committee (SEC) of CDSCO has approved its Investigational New Drug (IND) – Nor Ursodeoxy...

2025-03-12 05:30 3328

Flat Medical Announces Key U.S. Leadership Appointments

PITTSBURGH, PA., March 11, 2025 /PRNewswire/ -- Flat Medical announces strategic additions and promotions to its U.S. executive leadership team, positioning the company for continued growth in the North American medical technology sector. Mark Rabe has joined Flat Medical as Director of Sales an...

2025-03-11 22:30 2251

TraceLink Selected as a CIOReview Top Supply Chain Solution Provider of 2025

BOSTON, March 11, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the supply chain, has been recognized by CIOReview as a Top Supply Chain Solution Provider of 2025. This award highlights TraceLink's innovative approach to driving s...

2025-03-11 22:00 2068

WuXi XDC and AbTis Announce Strategic Partnership to Advance Next-Generation ADCs

SHANGHAI and SEOUL, South Korea , March 11, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates...

2025-03-11 21:20 2347

Milliken & Company Named One of the 2025 World's Most Ethical Companies®

For the 19th consecutive year, Ethisphere recognizes manufacturer's commitment to integrity and ethical business practices SPARTANBURG, S.C., March 11, 2025 /PRNewswire/ -- Milliken & Company is honored to be included onEthisphere's 2025 World's Most Ethical Companies list for the 19th consecuti...

2025-03-11 20:05 2720

Medit Set to Launch a New Intraoral Scanner, Medit i900 classic

SEOUL, South Korea and NEWPORT BEACH, Calif., March 11, 2025 /PRNewswire/ -- Medit (www.medit.com ), a global leader in digital dentistry, is set to unveil a new addition to itsi900 intraoral scanner lineup onMarch 25. Designed to enhance usability and efficiency, the upco...

2025-03-11 15:00 4235

Harbour BioMed Appoints Dr. Ian Y. Liu as Global Head of Legal

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, today announced ...

2025-03-11 08:00 2087

Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, today announced ...

2025-03-11 08:00 2166

Wingderm® Presents at the 2025 AAD Annual Meeting, Strengthening Its Presence in the North American Market

BEIJING, March 10, 2025 /PRNewswire/ -- Wingderm® once again participated in the 2025 AAD Annual Meeting, which was held inOrlando, Florida, from March 7 to 9. The American Academy of Dermatology is the largest, most influential, and most representative dermatologic association. During the event,...

2025-03-11 01:00 2819

Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity

BEIJING and BRIDGEWATER, N.J., March 10, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced that the first participant has been successfully dosed in a Phase 2 clinical trial of bofanglutide (research code: GZR18) injection, a bi-weekly glucagon-...

2025-03-10 23:45 2762

Sunway Medical Centre named top Malaysian Hospital in Newsweek's World's Best Hospitals ranking

SUBANG JAYA, Malaysia, March 10, 2025 /PRNewswire/ -- Sunway Medical Centre, Sunway City (SMC) has yet again ranked in the top 250 hospitals globally in the latest Newsweek's World's Best Hospitals 2025 rankings. (from left) Dato Lau Beng...

2025-03-10 21:59 4068

World's First Large-Scale, Multicenter Prospective Study in Single-Reading Mammography Confirms Lunit AI Boosts Cancer Detection

Prospective study finds Lunit AI increases cancer detection by 13.8% in single-reader settings without raising recall rates, presenting a game-changing tool for countries relying on single-reader mammography screening SEOUL, South Korea, March 10, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a le...

2025-03-10 21:00 2756

Gleneagles Hospital Hong Kong pioneers transformative Histotripsy treatment for liver cancer in private sector in Asia

HONG KONG, March 10, 2025 /PRNewswire/ -- Gleneagles Hospital Hong Kong (Gleneagles) is excited to be the first private hospital inAsia to offer Histotripsy treatment, the transformative and non-invasive technology that uses high-intensity ultrasound waves to destroy tumours for liver cancer pati...

2025-03-10 20:30 2768

SPRIM Global Investments and OneIM Announce $300mn Joint Venture to Accelerate Clinical Trial Financing

SINGAPORE and NEW YORK, March 10, 2025 /PRNewswire/ -- SPRIM Global Investments ("SGI"), a global investment firm specializing in clinical-stage life sciences and pharma services based inSingapore, and One Investment Management ("OneIM"), a global alternative investment management firm, today ann...

2025-03-10 20:19 2821

Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) Approved for Marketing in Second Indication by NMPA for EGFRm NSCLC

CHENGDU, China, March 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) was approved ...

2025-03-10 19:22 2183

Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan

VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) inJapan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). H. Lundbeck A/S (Lundbeck) a...

2025-03-10 16:57 2086

Doer Biologics Completes Enrollment of the Phase 2 Clinical Study of DR10624 for Treatment of Severe Hypertriglyceridemia

HANGZHOU, China, March 9, 2025 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers,today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting...

2025-03-10 10:53 2184

RiboX Therapeutics Announces First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation

PRINCETON, N.J., March 9, 2025 /PRNewswire/ -- RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, today announced that the first patient was dosed last week in its first-in-human (FIH) Phase I/...

2025-03-10 09:30 2564

China Telecom and Partners Innovate Together! 5G UAV Medical Delivery Network Wins Global Mobile Award

HONG KONG, March 10, 2025 /PRNewswire/ -- On March 5, during the 2025 Mobile World Congress (MWC25), the 5G UAV medical delivery network solution jointly developed by China Telecom, Hangzhou Antwork Network Technology andZhejiang University was awarded the Global Mobile Award (GLOMO Award) for "B...

2025-03-10 08:39 3393

AIM Vaccine's Iteratively Upgraded Diploid Rabies Vaccine Approved for Clinical Trials, Showing Significantly Higher Efficacy than Marketed Diploid Rabies Vaccines

HONG KONG, March 10, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement onMarch 9, 2025, the company's research and development of a diploid rabies vaccine has recently received the Clinical Trial Approval Notice from the National Medic...

2025-03-10 08:00 3852
1 ... 137138139140141142143 ... 647